FDA supplemental approval: Leucovorin Calcium (Labeling)

AI Summary

This is an FDA supplemental approval for labeling changes to leucovorin calcium tablets across four oral formulations (5 mg, 10 mg, 15 mg, and 25 mg base). The record documents a regulatory action but does not contain clinical trial results, efficacy data, or comparative evidence; it confirms only that revised labeling has been approved by the FDA.

Plain-language summary

FDA supplemental approval for labeling changes to leucovorin calcium tablets; regulatory action confirming revised labeling without new clinical efficacy data.

Reported figures

Quoted from the source exactly as published.

Caveats

• This record does not contain clinical trial results, efficacy data, or safety outcomes.
• The specific labeling changes are not detailed in this regulatory record.
• No comparative effectiveness data or clinical evidence is reported.
• This is a labeling supplement only; no new indication, dose, or formulation approval is described.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.